A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC

NCT05849298 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

49

Enrollment

INDUSTRY

Sponsor class

Conditions

Prostatic Neoplasm

Interventions

DRUG: AAA617
DRUG: AAA517
DRUG: Piflufolastat F 18
DRUG: ARPI
DRUG: ADT
OTHER: Best supportive care

Sponsor

Novartis Pharmaceuticals